Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.
| Status: | Terminated |
|---|---|
| Conditions: | Neurology, Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 9/16/2017 |
| Start Date: | January 2016 |
| End Date: | December 21, 2016 |
Characterization of Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.
The purpose of this research is to characterize the effect of teriflunomide on the activation
of B-cells, as well as its capacity to modify B-cell cytokine secretion. The in-vitro
identified effects of teriflunomide on the expression of B-cell activation markers,
costimulatory and antigen presenting molecules, as well as on cytokine secretion, will then
be confirmed in a cohort of Relapsing Remitting Multiple Sclerosis (RRMS) patients treated
with this medication.
of B-cells, as well as its capacity to modify B-cell cytokine secretion. The in-vitro
identified effects of teriflunomide on the expression of B-cell activation markers,
costimulatory and antigen presenting molecules, as well as on cytokine secretion, will then
be confirmed in a cohort of Relapsing Remitting Multiple Sclerosis (RRMS) patients treated
with this medication.
Inclusion Criteria:
- confirmed diagnosis of RRMS according to McDonald's diagnostic criteria,
- age 18-55,
- an extended disability status score (EDSS) of 1.5-5.5.
Exclusion Criteria:
- Previous treatment with DMT.
We found this trial at
1
site
Univ of North Carolina Carolina’s vibrant people and programs attest to the University’s long-standing place...
Click here to add this to my saved trials
